Press Release
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
"Being named this year's Chair of the Conference for NASH Summit Europe recognizes all the hard work that Galectin has done to make a breakthrough in this troubling disease," says
Focused exclusively on NASH and replete with leading industry experts, NASH Summit Europe is designed to provide the latest insight and connections to solve the challenges many face from drug discovery to late stage clinical development. The theme of this year's conference is "Accelerate the Development of Your Nonalcoholic Steatohepatitis Drug Pipeline."
"NASH has proven to be incredibly difficult to diagnose, in turn creating a difficult drug development process," adds Traber. "For this reason, it is essential that both organizations developing a drug as well as developing novel non-invasive diagnostic tests collaborate to advance the treatment of NASH and accelerate the timelines to when effective therapies are available to patients."
As Chair of the Conference,
About
Galectin Therapeutics is dedicated to
developing novel therapies to improve the lives of patients with chronic liver and skin diseases and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are for treatment of severe atopic dermatitis, moderate-to-severe plaque psoriasis, and in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and
efficient development. Additional information is available at www.galectintherapeutics.com.
Contacts:
(678) 620-3186
ir@galectintherapeutics.com
News Provided by Acquire Media